Search Results

The Lubrizol Corporation announces the licensing of its novel excipient polymer technology, Apisolex™ excipient, to Welton Pharma (Welton).

Solecta, Inc. and The Lubrizol Corporation announced a new partnership today to develop and market novel membrane solutions that will improve productivity and drive greater efficiencies for the global separations industry.

The Lubrizol Corporation, a Berkshire Hathaway Company, announced that Rebecca Liebert has been named the company’s President and CEO, effective October 3, 2022.

The Lubrizol Corporation announced that Mary Rhinehart will serve as president and CEO on an interim basis, effective immediately.

Agno Pharma, a US-based, global pharmaceutical contract development and manufacturing organization, announced that it will acquire the Lubrizol Particle Sciences Inc. business.

The acquisition expands Lubrizol’s 3D printing design, prototyping, printing and post-processing capabilities

Lubrizol Life Science – Beauty is partnering with Canadian firm Advonex International Corp. to develop renewable ingredients for the beauty and personal care market.

As part of its ongoing commitment to diversity and inclusion as a key enabler of business success, Lubrizol has appointed Cheree Aspelin as the company’s first Chief Diversity Officer.

The Lubrizol Corporation has announced that the Contract Development and Manufacturing Organization (CDMO) Division of Lubrizol Life Science Health (LLS Health) is expanding its product development partnership with the Population Council, an international nongovernmental non-profit organization conducting research around critical health and development issues.

Lubrizol Advanced Materials’ TempRite® Engineered Polymers business, the global leader in CPVC resin and compounds, is pleased to announce it has successfully met all the sustainability requirements of +Vantage Vinyl™, an industry-wide sustainability initiative that engages companies across the entire U.S. vinyl value chain.